Retinal stem cell transplantation: Balancing safety and potential

Mandeep Singh, Susanna S. Park, Thomas A. Albini, M. Valeria Canto-Soler, Henry Klassen, Robert E. MacLaren, Masayo Takahashi, Aaron Nagiel, Steven D. Schwartz, Kapil Bharti

Research output: Contribution to journalReview article

Abstract

Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.

Original languageEnglish (US)
Article number100779
JournalProgress in Retinal and Eye Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Stem Cell Transplantation
Safety
Retinal Diseases
Blindness
Stem Cell Research
Phase II Clinical Trials
Clinical Trials, Phase I
Patient Safety
Cell- and Tissue-Based Therapy
Industry
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Singh, M., Park, S. S., Albini, T. A., Canto-Soler, M. V., Klassen, H., MacLaren, R. E., ... Bharti, K. (Accepted/In press). Retinal stem cell transplantation: Balancing safety and potential. Progress in Retinal and Eye Research, [100779]. https://doi.org/10.1016/j.preteyeres.2019.100779

Retinal stem cell transplantation : Balancing safety and potential. / Singh, Mandeep; Park, Susanna S.; Albini, Thomas A.; Canto-Soler, M. Valeria; Klassen, Henry; MacLaren, Robert E.; Takahashi, Masayo; Nagiel, Aaron; Schwartz, Steven D.; Bharti, Kapil.

In: Progress in Retinal and Eye Research, 01.01.2019.

Research output: Contribution to journalReview article

Singh, M, Park, SS, Albini, TA, Canto-Soler, MV, Klassen, H, MacLaren, RE, Takahashi, M, Nagiel, A, Schwartz, SD & Bharti, K 2019, 'Retinal stem cell transplantation: Balancing safety and potential', Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2019.100779
Singh, Mandeep ; Park, Susanna S. ; Albini, Thomas A. ; Canto-Soler, M. Valeria ; Klassen, Henry ; MacLaren, Robert E. ; Takahashi, Masayo ; Nagiel, Aaron ; Schwartz, Steven D. ; Bharti, Kapil. / Retinal stem cell transplantation : Balancing safety and potential. In: Progress in Retinal and Eye Research. 2019.
@article{2bbd0dd45cb843aba9a73bcf96b490c3,
title = "Retinal stem cell transplantation: Balancing safety and potential",
abstract = "Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.",
author = "Mandeep Singh and Park, {Susanna S.} and Albini, {Thomas A.} and Canto-Soler, {M. Valeria} and Henry Klassen and MacLaren, {Robert E.} and Masayo Takahashi and Aaron Nagiel and Schwartz, {Steven D.} and Kapil Bharti",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.preteyeres.2019.100779",
language = "English (US)",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Retinal stem cell transplantation

T2 - Balancing safety and potential

AU - Singh, Mandeep

AU - Park, Susanna S.

AU - Albini, Thomas A.

AU - Canto-Soler, M. Valeria

AU - Klassen, Henry

AU - MacLaren, Robert E.

AU - Takahashi, Masayo

AU - Nagiel, Aaron

AU - Schwartz, Steven D.

AU - Bharti, Kapil

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.

AB - Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=85072045185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072045185&partnerID=8YFLogxK

U2 - 10.1016/j.preteyeres.2019.100779

DO - 10.1016/j.preteyeres.2019.100779

M3 - Review article

C2 - 31494256

AN - SCOPUS:85072045185

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

M1 - 100779

ER -